Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Technology evaluation: Sch-58500, Canji.

Current opinion in molecular therapeutics - 1 Oct 2000

Barnard D L

Abstract excerpt

Sch-58500 is a gene therapy utilizing the p53 gene and is under development by Canji and Schering-Plough for the potential treatment of various types of cancer. It is in phase II/III clinical trials in the US for stage III ovarian cancer [328228,328893], phase II clinical trials for hepatocellular and colorectal cancer metastatic to the liver [273331,324279], and phase I clinical trials for several other types of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Biotechnology
Share to Genes, p53

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Therapy

Share to Genetic Vectors

Share to Mutation

Share to Neoplasms

Share to Safety

Source

Identifiers

PMID: 11249761

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Technology evaluation: Sch-58500, Canji.PMID 11249761Read ↗

Completed Clinical Trials of p53 Gene Therapy in Cancer: A ClinicalTrials.gov-Based AnalysisSemantic proximity Read ↗

Cancer therapy based on p53.Semantic proximity Read ↗

The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.Semantic proximity Read ↗

Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.Semantic proximity Read ↗

Applications of Recombinant Adenovirus-p53 Gene Therapy for Cancers in the Clinic in China.Semantic proximity Read ↗

5-Fluorouracil: mechanisms of action and clinical strategiesSemantic proximity Read ↗

Head and neck cancer: Response to p53‐based therapeuticsSemantic proximity Read ↗

The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.Semantic proximity Read ↗

INGN 201 (Advexin): adenoviral p53 gene therapy for cancer.Semantic proximity Read ↗

[p53 gene therapy for oral cancer].Semantic proximity Read ↗

Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.